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Abstract In an attempt to understand the molecular nature of 
Batten disease, we have examined the amino acid sequence of the 
affected CL&‘3 gene product (The International Batten Disease 
Consortium (1995) Cell 82, 949-957) and the site-specific 
mutations which give rise to the biological defect. Homology 
searches and molecular modeling have led to the development of a 
model for the folding and disposition of the protein, possibly 
within a mitochondrial membrane. High homology with a yeast 
protein of unknown function suggests a strong evolutionary 
conservation of function. We speculate that a possible role for the 
protein may be in chaperoning the folding/unfolding or assembly/ 
disassembly of other proteins, specifically subunit c of the 
mitochondrial ATP synthase complex. 
Key words: Molecular modeling; Chaperone; Genetic 
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1. Introduction 
Batten disease (juvenile onset ceroid lipofuscinosis [JNCL]) 
is one type of a group of autosomal recessive inherited neu- 
rodegenerative disorders characterized by the accumulation of 
autofluorescent lipopigment (ceroid and lipofuscin) in many 
tissues [2]. The clinical features include visual failure, seizures 
and psychomotor deterioration leading to a vegetative state 
and premature death in the third decade. The main compo- 
nent of the storage material deposited is subunit c of the 
mitochondrial ATP synthase complex [3,4]. The gene defective 
in Batten disease, CLN3, has recently been identified [l] and 
encodes a predicted protein of 438 amino acids. To rationalize 
the possible structural basis of the protein defects underlying 
Batten disease, we have constructed a model of the CLN3 
protein (Fig. 1). 
2. Materials and methods 
The sequence homology studies were performed using the BLAST 
[5] algorithm. Sequence alignment with the yeast protein, SWISS- 
PROT [6] entry YJF9_YEAST, was performed using Multalin [7] 
with a gap weight of 8 and gap length weight of 0. PSORT [S] was 
used to identify mitochondrial recognition and cleavage site data. The 
FOAMV86 [9] package, using the GES [9], Kyte and Doolittle [lo], 
and Wolfenden [l l] scales, each with a window size of 20, was used to 
produce hydrophobicity plots for visual analysis. The scanPROSITE 
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[12] tool was used to find motifs consistent with N-glycosylation sites, 
and potential phosphorylation sites by CAMP- and cGMP-dependent 
protein kinase, protein kinase c, and casein kinase II. NetOglyc [13] 
was used to find motifs consistent with O-glycosylation sites. All other 
searches were performed manually. 
3. Results and discussion 
The first aim was to establish whether the CLN3 protein 
was a membrane or soluble protein. Calculation of the overall 
average hydrophobicity of the sequence using the GES [9] and 
Eisenberg [14] scales, gave values of 0.256 and 0.253, respec- 
tively. Using the same scales, myoglobin, a typical soluble 
protein, produced values of -0.094 and 0.008, and bacterio- 
rhodopsin, an extremely hydrophobic membrane protein, gave 
0.315 and 0.363. Thus, the CLN3 protein is significantly hy- 
drophobic in character, consistent with it being an integral 
membrane protein. Hydrophobicity plots using GES, Kyte 
and Doolittle [lo], and Wolfenden [1 l] scales suggest the ex- 
istence of six transmembrane segments (TMS), as shown in 
Fig. 1 and Table 1. The sequence appears to have a mitochon- 
drial targeting site at residue 11, with a cleavage site at residue 
19 for mitochondrial proteins, which suggests that CLN3 is 
associated with a mitochondrial membrane. As expected for a 
realistic model, the predicted N-glycosylation sites at residues 
49, 71, 85, and 310, were found in our model structure to lie 
only on one surface (Fig. 1), a surface which could be con- 
sidered topologically equivalent to the exoplasmic surface. In 
this paper we will refer to this as the ‘exo’ surface. Also con- 
sistent with a reasonable model, none of the predicted phos- 
phorylation sites were found to be in a TMS (Fig. 1). Two 
putative U-glycosylation sites exist at residues 80 and 256, and 
our model placed one of these on the N-terminal exo surface 
and the other on the opposite face, in a ‘cyto’ loop. However, 
as 0-glycosylation sites are poorly defined and not necessarily 
utilized [15], this is not considered a significant problem. 
There is only a single cysteine on the cyto surface; all other 
extramembranous cysteine residues are on the exo loops. This 
means that no disulphide bonds could be formed on the cyto 
surface of the protein although some could form on the exo 
surface, again consistent with the expectations for a correct 
model. There are seven positively charged residues in the cyto 
loops, but only six in the exo loops, which is consistent with 
the general observation of a more positively charged cyto sur- 
face. Furthermore, for mitochondrial proteins such a charge 
asymmetry is not expected to be very pronounced, as is the 
case here. Tryptophan residues within the TMS of our model 
are at, or very near to, the ends of the transmembrane do- 
mains, which is consistent with known X-ray structures of 
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Fig. 1. Schematic model for the putative structural arrangement of CLN3 Batten disease protein showing the six transmembrane segments 
(TMS) and highlighting locations of potential extramembranous N-glycosylation and phosphorylation sites and Cys residues, and the positions 
of Trp and charged residues within the TMS. 
proteins containing TMS. Five potentially charged residues 
fall within the TMS of our model, which at first would appear 
to be energetically unfavourable, but their spatial arrange- 
ments are such that ion-pairs could be formed between 
Lys”2 (TMSl), and either Asp3’j2 (TMSS), or G1u381 
(TMS6), thus leaving only three unpaired charges. It is nota- 
ble that if either of the proposed salt bridges is formed, this 
would impose constraints on the 3-dimensional folding of the 
polypeptide. 
A homology search has identified a yeast protein in S. cere- 
visiue, (SWISS-PROT [6] entry YJF9YEAST) which has 36% 
identity and 56% similarity with the CLN3 protein (Fig. 2). 
This is the only protein of known sequence in the public 
databases to date with which CLN3 has significant homology, 
and is a further example of the trend [16] of correspondence 
between yeast and human disease genes. A subsequent exam- 
Table 1 
Homology analysis of the individual domains of CLN3 compared 
with the yeast protein YJF9YEAST 
Domain Residues 
N-terminal l-97 
TMSl 98-l 19 
Loop 1 120-138 
TMS2 139-160 
Loop 2 161-212 
TMS3 213-234 
Loop 3 235-280 
TMS4 281-303 
Loop 4 304-345 
TMS5 346368 
Loop 5 369-370 
TMS6 371-393 
C-terminal 394438 
Percentage identity 
22 (21/97) 
55 (12/22) 
32 (6119) 
45 (10/22) 
52 (27152) 
18 (4/22) 
20 (9/46) 
57 (13/23) 
40 (17/42) 
30 (7/23) 
50 (112) 
61 (14/23) 
40 (1X/45) 
ination of the alignments of the individual N-termini, surface 
loops, TMS and C-termini domains, of the CLN3 and yeast 
proteins showed that the entire CLN3 and yeast proteins pos- 
sess a high level of homology, with slightly higher homology 
in the exo loops and in three of the six TMS. One noteworthy 
feature in this case is that all of the known single point muta- 
tion sites which have been found in the CLN3 protein of 
Batten disease patients thus far (Munroe, P.B. et al., in prep- 
aration), at residues 101, 170, 295, 330, and 334, are found at 
sites which have identical residues in the yeast protein, three 
of which are in TMS, and two in exo loops. Of the five TMS 
charges found in the CLN3 protein, four of them are found in 
the yeast protein. That the equivalent residue to Asp362 of the 
CLN3 protein is not a charged residue in the yeast protein, 
suggests that the charged pairing in the CLN3 protein in- 
volves TMSl and TMS6, and not TMSS. 
Finally, it is of note that no significant homology is found 
with any prokaryotic protein known to date, suggesting a 
function that is conserved and specific to eukaryotes. The 
slow rate of evolutionary divergence between the CLN3 and 
yeast protein suggests it is involved in interactions with other 
proteins. The percentage identity is comparable to that found 
for other pairs of human/yeast proteins which are involved in 
assembly processes. Therefore, we postulate that amongst 
other possibilities, the function of the CLN3 protein could 
be as a chaperone involved in the folding or unfolding path- 
ways of subunit c of the ATP synthase complex. This is con- 
sistent with recent biochemical evidence suggesting a chaper- 
oning role for the Batten disease gene product [17]. The 
residues in CLN3 which show mutations in Batten disease 
patients, and are identical to residues in the yeast protein, 
clearly play an important role in the function and/or structur- 
al integrity of the CLN3 protein, and would indicate the 
R. W. Janes et al.IFEBS Letters 399 (1996) 75-77 
CLN3 RRRFSDSEGEETVPEPRLPLLDHQGAHWKNAVG xi 
YJFS_YEAST HQIYCY........................... V 
CLN3 
YJF9_YEAST 
CLN3 
YJFg_YEAST 
CLN3 
YJFg_YEAST 
CLN3 
YJF9_YEAST 
CLN3 
YJFS_YEAST 
CLN3 
YJFg_YEAST 
CLN3 
YJF9_YEAST 
SHKRTSGNQSHVDP PIPHNSSSRFDCNSVSTAA 
. . . . . . . . . . . . . . 
P&V..&lSGI@AA 
Y&IWS%ITMS@L. 
179 AVISW QAGLS$$QQTL&SMLGIPALLLAS 
121 ISLNG SIFKVbVKLTdLVFSLLPFAFLF 
239 PGGEEEAES#$ARQP~IRTEAPESKPGS;#S 
181 YQSLQQIDE#EDDQ@rPFPVAFTHTNAMQ 
.@L$iERW..@.. FKGSLW . $$@@VV%j: 
Y~~T~QHILQ~~KRLRR~~FP~M~~~TT~~ 
293 FA F&%@GLFEL%FF. 
241 LF L,#&AVAPT$L#P 
342 IRFTWA#%kL&&L@VFLLADV 
301 M+SLYI##F@jGV#&+CITVLQS 
GFLPPIYLVjFLI$L 
YVTH&PWA@MIL.$F 
402 DEHR~~A~TC~S~TLGIS%@3G@#A~P~HDFti~..QLS.~..~.... 
361 PDET###F$GWVS~AHSFGVF~AA#@,tG~GHEPK#GRH~IADDRPWCRME 
Fig. 2. Sequence alignment between the CLN3 Batten disease protein and the yeast protein, code YJF9_YEAST in SWISS-PROT. The identical 
residues between the proteins are highlighted by a grey background while the CLN3 protein point mutation sites found in Batten disease pa- 
tients are shown with a black background. 
CLN3 protein interacts with other molecules via its exo sur- 
face. 
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